Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Specific gut microbiota alterations and metabolic deficits in Parkinson's disease: a controlled comparison with functional constipation.

Frontiers in cellular and infection microbiology·2026

Same author

Luminescent Properties and Optical Temperature Sensing Performance of CaTa<sub>2</sub>O<sub>6</sub>:Pr<sup>3+</sup> Phosphors Under Blue-Light Excitation.

Materials (Basel, Switzerland)·2026

Same author

The Effects of Different Culture Modes on the Nutritional Quality of <i>Procambarus clarkii</i> and Mechanistic Insights: A Metabolomic Perspective.

Biology·2026

Same author

Pharmacoeconomic Evaluation of Netupitant Palonosetron for Chemotherapy-Induced Nausea and Vomiting: Evidence from Economic Analyses.

Therapeutic innovation & regulatory science·2026

Same author

Hemoglobin-Based Oxygen Carriers Promoted the Antitumor Effect of <sup>177</sup>Lu-PSMA-617 by Enhancing DNA Repair Capacity of Immune Cells.

Cancer biotherapy & radiopharmaceuticals·2026

Same author

Deciphering microenvironmental heterogeneity by scalable Niche Guided Module Discovery.

Communications biology·2026

Search research articles

Related Experiment Video

Updated: Sep 27, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Immune targeted therapy for diffuse large B cell lymphoma.

Yaxin Zheng¹, Junqi Si¹, Tian Yuan¹

¹Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Blood Science (Baltimore, Md.)

|April 11, 2022

Summary

This summary is machine-generated.

Diffuse large B-cell lymphoma (DLBCL) is a common cancer with a poor prognosis for some. This review covers advancements in immune-targeted therapies, including bispecific T-cell engagers and CAR T-cell therapy, for refractory and relapsed DLBCL patients.

Keywords:

Antibody-drug conjugates Checkpoint inhibitors DLBCL Monoclonal antibodies Signaling pathway inhibitors

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Sep 27, 2025

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Oncology
Immunology

Background:

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, characterized by heterogeneity and invasiveness.
While many patients respond to standard chemoimmunotherapy (R-CHOP), approximately one-third face a poor prognosis.
Refractory and relapsed DLBCL present significant clinical challenges.

Purpose of the Study:

To review the current progress and advancements in immune-targeted therapies for DLBCL.
To highlight the efficacy of novel immunotherapies in managing refractory and relapsed DLBCL cases.

Main Methods:

Literature review of recent clinical studies and research on immune-targeted therapies for DLBCL.
Analysis of data concerning bispecific T-cell engagers and CAR T-cell therapy efficacy.

Main Results:

Immune-targeted therapies, including bispecific T-cell engagers and CAR T-cell therapy, demonstrate significant efficacy in patients with refractory and relapsed DLBCL.
These novel approaches offer promising alternatives for a subset of DLBCL patients who do not respond to conventional treatments.

Conclusions:

Immune-targeted therapy represents a rapidly evolving and effective strategy for treating difficult-to-manage DLBCL.
Continued research and development in this area hold potential for improving outcomes for a broader range of DLBCL patients.